Gesamter Bestand

Auflistung Nach Schlagwort "Rituximab"

Anzeige der Dokumente 1-11 von 11

    • FcγRIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: A meta-analysis of genetic risk 

      Ziakas P.D., Poulou L.S., Zintzaras E. (2016)
      Purpose: Low-affinity variants FcγRIIIa-V158F and FcγRI-Ia-H131R may alter response to rituximab-based chemotherapy in diffuse large B-cell lymphoma (DLBCL) but available clinical evidence is inconclusive. Our purpose was ...

    • Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat 

      Zachou, K.; Sarantopoulos, A.; Gatselis, N. K.; Vassiliadis, T.; Gabeta, S.; Stefos, A.; Saitis, A.; Boura, P.; Dalekos, G. N. (2013)
      AIM: To present the characteristics and the course of a series of anti- hepatitis B virus core antibody (HBc) antibody positive patients, who experienced hepatitis B virus (HBV) reactivation after immunosuppression. METHODS: ...

    • Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP 

      Vassilakopoulos T.P., Michail M., Papageorgiou S., Kourti G., Angelopoulou M.K., Panitsas F., Sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Terpos E., Dimopoulou M.N., Karakatsanis S., Michalis E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Economopoulos T., Kyriazopoulou L., Siakantaris M.P., Kyrtsonis M.-C., Symeonidis A., Anargyrou K., Papaioannou M., Hatjiharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Gainaru G., Stefanoudaki E., Zikos P., Tsirigotis P., Tsourouflis G., Assimakopoulou T., Konstantinidou P., A. Papadaki H., Megalakaki K., Dimopoulos M.-A., Pappa V., Karmiris T., Roussou P., Panayiotidis P., Konstantopoulos K., Pangalis G.A. (2021)
      Background: R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective ...

    • Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching 

      Declerck P., Bakalos G., Zintzaras E., Barton B., Schreitmüller T. (2018)
      Purpose: With the introduction of biosimilars of anticancer monoclonal antibodies (mAbs) in oncology, physicians are potentially confronted with the question whether it is clinically adequate to switch patients who are ...

    • A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease 

      Daoussis D., Melissaropoulos K., Sakellaropoulos G., Antonopoulos I., Markatseli T.E., Simopoulou T., Georgiou P., Andonopoulos A.P., Drosos A.A., Sakkas L., Liossis S.-N. (2017)
      Objectives Rituximab (RTX) may favorably affect lung function and skin fibrosis in patients with systemic sclerosis (SSc). We aimed to assess long-term efficacy and safety of RTX in SSc compared to standard treatment. ...

    • On the efficacy and safety of rituximab therapy in patients with systemic sclerosis disease: missing points, bottlenecks, over-exaggeration, and discrepancies—comments on the article by Moradzadeh et al. 

      Gkiouras K., Grammatikopoulou M.G., Bogdanos D.P. (2021)
      [No abstract available]

    • Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies 

      Vassilakopoulos T.P., Papageorgiou S.G., Angelopoulou M.K., Chatziioannou S., Prassopoulos V., Karakatsanis S., Arapaki M., Mellios Z., Sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Terpos E., Michali E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Siakantaris M.P., Kyrtsonis M.-C., Symeonidis A., Anargyrou K., Papaioannou M., Chatziharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Gainaru G., Mainta C., Tsirigotis P., Assimakopoulou T., Konstantinidou P., Papadaki H., Dimopoulos M.-A., Pappa V., Karmiris T., Roussou P., Datseris I., Panayiotidis P., Konstantopoulos K., Pangalis G.A., Rondogianni P. (2021)
      End-of-treatment (EoT) PET/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective study evaluating the ...

    • Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma 

      Karakatsanis S.J., Bouzani M., Symeonidis A., Angelopoulou M.K., Papageorgiou S.G., Michail M., Gainaru G., Kourti G., sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Kanellias N., Dimopoulou M.N., Michali E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Economopoulos T., Kyriazopoulou L., Siakantaris M.P., Kyrtsonis M.-C., Anargyrou K., Papaioannou M., Hatjiharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Stefanoudaki E., Zikos P., Tsirigotis P., Tsourouflis G., Assimakopoulou T., Verrou E., Papadaki H., Lampropoulou P., Dimopoulos M.-A., Pappa V., Konstantopoulos K., Karmiris T., Roussou P., Panayiotidis P., Pangalis G.A., Vassilakopoulos T.P. (2022)
      Background/Aim: Primary mediastinal large Bcell lymphoma (PMLBCL) is an aggressive B-cell non- Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody ...

    • A revised international prognostic score system for Waldenström’s macroglobulinemia 

      Kastritis E., Morel P., Duhamel A., Gavriatopoulou M., Kyrtsonis M.C., Durot E., Symeonidis A., Laribi K., Hatjiharissi E., Ysebaert L., Vassou A., Giannakoulas N., Merlini G., Repousis P., Varettoni M., Michalis E., Hivert B., Michail M., Katodritou E., Terpos E., Leblond V., Dimopoulos M.A. (2019)
      A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in ...

    • Rituximab Administered for Recurrent Membranous Nephropathy in a Kidney Transplant Recipient Did Not Eliminate Donor-Specific Antibodies 

      Giannopoulou M., Tarassi K., Tsouka G., Christodoulidou C., Stefanidis I., Eleftheriadis T. (2022)
      Chronic active antibody-mediated rejection is the leading cause of kidney transplant failure. Although various immunosuppressive agents have been tested, rituximab included, presently there is no effective treatment. There ...

    • Targeting very early systemic sclerosis: a case-based review 

      Melissaropoulos K., Kraniotis P., Bogdanos D., Dimitroulas T., Sakkas L., Daoussis D. (2019)
      It is unknown whether treatment in very early/early systemic sclerosis (SSc) can affect long-term outcomes. A case-based review was conducted (i) to assess the effect of rituximab (RTX) in very early SSc and (ii) to explore ...